17,261 trials
Advanced Solid Tumors
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 1; 0; 2; 0 Participants
Breast Adenocarcinoma · Deleterious BRCA1 Gene Mutation · Deleterious BRCA2 Gene Mutation
Primary: Number of Participants With Overall Pathological Complete Response (pCR) — 7; 10; 3; 2 Participants
Schizophrenia
Primary: The Incidence of Overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation — 88; 15; 18; 18 Participants
Hidradenitis Suppurativa
Primary: Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.1; 59.5; 57.3 Percentage of…
Attention Deficit Hyperactivity Disorder
Primary: CASI-5 Parent-rated Composite Score — 1.49; 1.52; 1.18; 1.23 score on a scale
Advanced Cancers
Primary: Progression-Free Rate at 4 Month — 25; 10; 44.4; 75 percentage of participants
Hormone Receptor Positive Breast Cancer
Primary: First-line Treatment: Progression-free Survival (PFS) — NA Months
Crohn Disease
Primary: Change in FCP in Group 2 Participants — 1501 mcg/g — p=1.0
ST Elevation Myocardial Infarction
Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size
Psoriasis
Primary: Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84 — -1.07; -2.25; -2.47; -2.27 score on a scale — p=0.0041
Prostate Cancer
Primary: Objective Response Rate Per Prostate Cancer Clinical Trials Working Group 3 (ORR-PCWG3) — 10.3; 15.4; 40.0; 11.1 Percentage of participants
Acute Pain
Primary: Time-weighted Sum of the Pain Intensity Difference as Recorded on Numeric Pain Rating Scale (NPRS) 0 to 24 Hours (SPID24) After First Dose — 19.1; 37.3; 32.3; 30.5 units…
Dysautonomia, Familial · Baroreflex Failure Syndrome
Primary: Number of Participants Who Reported Adverse Events Related to Study Drug — 0; 0; 0 Participants
Leukemia
Primary: Maximum Tolerated Dose (MTD) of Vosaroxin in Combination With Decitabine — 70 Mg/m^2
Huntington Disease
Primary: Number of Patients With at Least One Adverse Event — 119 Participants